Wed, Jul 23, 2014, 12:38 AM EDT - U.S. Markets open in 8 hrs 52 mins

Recent

% | $
Click the to save as a favorite.

Skullcandy, Inc. (SKUL) Message Board

cash2go 124 posts  |  Last Activity: 23 hours ago Member since: Feb 8, 2006
  • Reply to

    Take-out?

    by seancoach Apr 17, 2014 11:23 AM
    cash2go cash2go Apr 23, 2014 2:13 AM Flag

    Per Motley Fool

    Portola Pharmaceuticals may soon turn the world of blood thinners on its head. Less than a year after its IPO, the company has an oral once-daily inhibitor of Factor Xa, named betrixaban, in a pivotal Phase 3 trial for the prevention of blood clots known as venous thromboembolisms (VBTs).

    After various types of surgery, patients are typically given enoxaparin as an injection in a hospital setting. The drug itself is safe, but keeping it at an effective level in the bloodstream is difficult. Due to this difficulty, the therapy is typically stopped when they're sent home. Far too often, patients then develop blood clots that pose serious health risks and require rehospitalization.

    Betrixaban is a pill that can be taken once daily to continue prevention of VBTs without extensive monitoring. So far, it appears to maintain effective levels in the bloodstream without going overboard. Payers often penalize hospitals if patients are rehospitalized shortly after their discharge. If approved, betrixaban is likely to be very widely prescribed, saving health care providers a bundle.

    *((Betrixaban would be a true blockbuster for a J&J purchase)) Buying before phase III is underway would be logical?

  • Reply to

    Take-out?

    by seancoach Apr 17, 2014 11:23 AM
    cash2go cash2go Apr 23, 2014 2:11 AM Flag

    Portola Pharmaceuticals Appoints John H. Johnson to Board of Directors

    said William Lis, chief executive officer of Portola. "Personally, I'm pleased to be working with John again, having had prior success under his leadership at Johnson & Johnson with the anticoagulant XARELTO."

    Buyout? Makes more sense as I dig through history of partnerships.

  • Reply to

    Take-out?

    by seancoach Apr 17, 2014 11:23 AM
    cash2go cash2go Apr 23, 2014 2:04 AM Flag

    Why J&J? It would help sales of Xarelto catch Eliquis. If the Xarelto/Andexanat trial were completed 6 months ahead of others it would be a nice head start.

  • Reply to

    Take-out?

    by seancoach Apr 17, 2014 11:23 AM
    cash2go cash2go Apr 23, 2014 2:00 AM Flag

    Portola to Receive Upfront and Milestone Payments While ((Retaining Full Worldwide Rights)) to Andexanet Alfa

    (Three sources of payouts are coming from) :
    1. BMS/Pfizer
    2. J&J - Bayer
    3. Daiichie

    On a drug the FDA designated as breakthrough therapy and is giving accelerated approval. While Retaining Full Worldwide Rights to Andexanet Alfa.

    Now that the Daiichie contract is in place the FDA can feel assured the Phase III trials for antidotes to all three drugs will be given full effort at accelerated approval by Portola. The Daiichie contract may have been needed before approval of a buyout??? (My guess J&J)

SKUL
7.26+0.07(+0.97%)Jul 22 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.